How well does Agamree(Vamorolone) work?

AGAMREE improves motor function in pediatric DMD patients, validated by clinical trials.

Efficacy in Duchenne Muscular Dystrophy

AGAMREE demonstrated efficacy in a 24-week randomized trial (N=121) of ambulatory DMD patients aged 4–7 years. The 6 mg/kg/day dose significantly improved Time to Stand (TTSTAND) velocity (LS mean difference: 0.060 rises/sec vs. placebo, p=0.002) and 6-Minute Walk Test (6MWT) distance (+42 meters, p=0.002). These outcomes reflect preserved muscle strength and mobility. The 2 mg/kg/day dose showed intermediate efficacy but lacked statistical significance for some endpoints. The mechanism remains unclear but involves glucocorticoid receptor-mediated anti-inflammatory effects. No data support use in non-ambulatory or geriatric DMD patients.

Related Columns

Vamorolone(Agamree)

Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.

WeChat Scan
Free Inquiry

How Effective is Agamree in Treatment?

Agamree is an innovative glucocorticoid drug with Vamorolone as its main active ingredient. It is the first treatment for Duchenne Muscular Dystrophy (DMD) to receive full approval in the European Uni...

Vamorolone information and treatment effects

Vamorolone (trade name Agamree, also known as Vamorolone) is an innovative drug for the treatment of Duchenne muscular dystrophy (DMD) developed by Swiss pharmaceutical company Santhera Pharmaceutical...